HPV疫苗对男男性行为者肛管HPV感染的有效性:年龄、性活跃年限与HIV状态的影响
该研究在加拿大三个城市招募1159名≥16岁性活跃的男男性行为者(GBM),比较2019-2021年疫苗可预防型肛管HPV的患病率。结果显示,在16-26岁组中,≤23岁接种、首剂后≥3年及接种前性活跃≤5年者HPV6/11/16/18患病率显著降低;27-45岁组中≤26岁接种者九价HPV型患病率降低但未达统计学显著性。
要点
- 年轻GBM在≤23岁或性 début 前接种HPV疫苗可显著降低HPV6/11/16/18感染。
- 27-45岁组中≤26岁接种者九价型感染率有下降趋势但无统计学意义。
- HIV感染者占17.6%,不同年龄组接种率差异较大。
核心结论
- 在加拿大HPV疫苗接种规划实施五年后,年轻接种年龄和接近性 début 时接种的GBM肛管HPV患病率更低。
研究设计与样本
- 2019-2021年在蒙特利尔、多伦多和温哥华采用受访者驱动抽样(RDS)招募≥16岁性活跃GBM,自报接种状态并自采肛管HPV标本,共纳入1159名18-83岁参与者(中位35岁)。
主要发现
- 16-26岁组中,≤23岁接种者HPV6/11/16/18患病率aPR=0.40(95%CI 0.20-0.77),首剂后≥3年者aPR=0.39(95%CI 0.18-0.85),接种前性活跃≤5年者aPR=0.47(95%CI 0.25-0.89)。
- 27-45岁组中,≤26岁接种者HPV6/11/16/18/31/33/45/52/58患病率aPR=0.81(95%CI 0.61-1.08),未达统计学显著性。
临床怎么用
- 应优先在性 début 前或年轻年龄(≤23岁)为GBM接种HPV疫苗以降低肛管HPV感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We compared the prevalence of vaccine-preventable anal human papillomavirus (HPV) types among gay, bisexual, and other men who have sex with men (GBM) living in large cities in Canada from 2019 to 2021 by age and HIV status. METHODS: Sexually-active GBM ≥16 years were recruited in Montreal, Toronto, and Vancouver using respondent-driven sampling (RDS). Participants self-reported HPV vaccination and self-collected anal HPV specimens. We estimated the prevalence of vaccine-preventable types for participants during the 2019 to 2021 period. We report RDS-II-weighted prevalence and confounder-adjusted prevalence ratios (aPRs) comparing vaccinated (≥1 dose) and unvaccinated GBM using multivariable Poisson regression. RESULTS: Among 1,159 participants aged 18-83 (median 35 years), 17.6% were living with HIV, and 62.2%, 40.2% and 15.0% were vaccinated in the 16-26, 27-45, and ≥46-year groups, respectively. Among GBM 16-26 years, HPV6/11/16/18 prevalence was lower among those vaccinated ≤23 years (aPR= 0.40, 95% CI: 0.20-0.77), ≥3 years since first dose (aPR=0.39; 95% CI: 0.18-0.85), and those with ≤5 years of sexual activity before vaccination (aPR=0.47; 95%CI: 0.25-0.89). HPV6/11/16/18/31/33/45/52/58 prevalence was lower among those vaccinated ≤26 years in GBM aged 27-45 years (aPR= 0.81, 95% CI, 0.61-1.08), though this did not reach statistical significance. CONCLUSIONS: Five years after implementation of Canadian HPV vaccination programs for younger GBM, anal HPV prevalence was lower among those vaccinated at younger ages and near sexual debut.
引用
- Khayargoli P, Grace D, Cox J, et al. HPV vaccine effectiveness against prevalent HPV by age, years sexually active before vaccination, and HIV status in gay, bisexual, and other men who have sex with men, 2019-2021. J Infect Dis. 2026. PMID: 42642045. doi:10.1093/infdis/jiag426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。